Your browser doesn't support javascript.
loading
Developing a generic business case for an advanced chronic liver disease support service.
Wright, Mark; Willmore, Sarah; Verma, Sumita; Omasta-Martin, Anita; Sahota, Humraj; Prentice, Wendy; Stockley, Amelia Jane; Finlay, Fiona; Verne, Julia; Hudson, Ben.
Afiliação
  • Wright M; Hepatology, University Hospital Southampton, Southampton, Hampshire, UK.
  • Willmore S; Hepatology, University Hospital Southampton, Southampton, Hampshire, UK.
  • Verma S; Clinical and Experimental Medicine, Brighton and Sussex Medical School, Brighton, East Sussex, UK.
  • Omasta-Martin A; Gastroenterology and Hepatology, Brighton and Sussex University Hospitals NHS Trust, Brighton, UK.
  • Sahota H; Palliative Care, University Hospital Southamptom, Southampton, UK.
  • Prentice W; Hepatology, University Hospital Southampton, Southampton, Hampshire, UK.
  • Stockley AJ; Department of Palliative Care Medicine, King's College Hospital NHS Foundation Trust, London, London, UK.
  • Finlay F; Supportive and Palliative Care, Royal Devon and Exeter NHS Foundation Trust, Exeter, Devon, UK.
  • Verne J; Palliative Care, Queen Elizabeth University Hospital Campus, Glasgow, UK.
  • Hudson B; Public Health, United Kingdom Department of Health and Social Care, London, UK.
Frontline Gastroenterol ; 15(2): 104-109, 2024 Mar.
Article em En | MEDLINE | ID: mdl-38486664
ABSTRACT

Introduction:

Liver disease deaths are rising, but specialist palliative care services for hepatology are limited. Expansion across the NHS is required.

Methods:

We surveyed clinicians, patients and carers to design an 'ideal' service. Using standard NHS tariffs, we calculated the cost of this service. In hospitals where specialist palliative care was available for liver disease, patient-level costs and bed utilisation in last year of life (LYOL) were compared between those seen by specialist palliative care before death and those not.

Results:

The 'ideal' service was described. Costs were calculated as whole time equivalent for a minimal service, which could be scaled up. From a hospital with an existing service, patients seen by specialist palliative care had associated costs of £14 728 in LYOL, compared with £18 558 for those dying without. Savings more than balanced the costs of introducing the service. Average bed days per patient in LYOL were reduced (19.4 vs 25.7) also intensive care unit bed days (1.1 vs 1.8). Despite this, time from first admission in LYOL to death was similar in both groups (6 months for the specialist palliative care group vs 5 for those not referred).

Conclusions:

We have produced a template business case for an 'ideal' advanced liver disease support service, which self-funds and saves many bed days. The model can be easily adapted for local use in other trusts. We describe the methodology for calculating patient-level costs and the required service size. We present a financially compelling argument to expand a service to meet a growing need.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article